PATINA trial studies targeted therapy for breast cancer
August 28, 2017
Patients with hormone-receptor-positive, HER2-positive metastatic breast cancer may qualify for a newly opened clinical trial at Providence Cancer Center. The PATINA trial expects to demonstrate that adding the targeted therapy palbociclib to standard therapies (anti-HER2 therapy plus endocrine therapy) will delay therapeutic resistance and prolong survival over standard therapies alone. Half of the patients in the study will receive palbociclib, and all participants will receive the first-line standard therapies.
Providence Cancer Center is one of only a handful of centers in the United States participating in this study. Medical oncologist Alison Conlin, M.D., is the principal investigator.
View the study here.
For more information about the study, visit patina-trial.com or clinicaltrials.gov.
29 breast cancer studies are currently open
The PATINA trial is one of 29 ongoing research studies investigating a broad spectrum of breast cancer therapies and interventions at Providence Cancer Center. We offer studies aimed at improving cure rates, quality of life and survival for both early-stage and metastatic breast cancer patients. These studies range from small phase I clinical trials to larger international studies, including offerings from the National Cancer Institute, our own NCI Community Oncology Research Program (the Pacific Cancer Research Consortium), and pharmaceutical industry partners. Our own investigator-initiated research studies, available exclusively at Providence Cancer Center, focus on novel approaches that harness the immune system to treat cancer.
New research studies are added frequently. For a complete list of all current breast cancer studies at Providence Cancer Center, please visit our website. For more information, call our Clinical Trials office at 503-215-2614.
A team of breast cancer specialists
The research team at the Earle A. Chiles Research Institute at Providence Cancer Center includes oncologists who specialize exclusively in breast cancer, as well as breast-cancer-focused research nurses, laboratory scientists, data coordinators and lab assistants. Every person on this team is passionate about providing the best possible care and the best available study options for patients with breast cancer.